Skip to main content

Advertisement

Table 4 Multivariable analysis of prognostic factors of all 82 NPC patients with residual cervical lymphadenopathy

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Variable PFS OS DMFS LRRFS LRFS RRFS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age 0.827 (0.408–1.675) 0.598 1.604 (0.625–4.113) 0.326 0.440 (0.148–1.308) 0.140 0.728 (0.331–1.600) 0.429 0.619 (0.224–1.715) 0.357 1.328 (0.507–3.479) 0.564
Sex 0.699 (0.336–1.454) 0.338 0.503 (0.164–1.542) 0.230 0.467 (0.148–1.472) 0.194 0.533 (0.237–1.197) 0.127 0.531 (0.189–1.492) 0.230 0.585 (0.211–1.619) 0.302
T stage 2.739 (1.173–6.397) 0.020 4.114 (1.140–14.847) 0.031 10.722 (2.408–47.740) 0.002 1.536 (0.611–3.861) 0.361 1.433 (0.437–4.702) 0.553 2.606 (0.803–8.465) 0.111
N stage 2.735 (0.761–9.837) 0.123 2.530 (0.577–11.090) 0.218 9.408 (1.465–60.435) 0.018 1.475 (0.367–5.927) 0.583 2.379 (0.359–15.749) 0.369 2.085 (0.416–10.446) 0.372
Clinical stage 0.516 (0.214–1.246) 0.142 1.309 (0.421–4.071) 0.642 0.384 (0.095–1.549) 0.179 0.637 (0.266–1.530) 0.313 0.408 (0.120–1.392) 0.152 0.740 (0.244–2.242) 0.594
EBV DNA before first treatment 1.360 (0.658–2.811) 0.407 0.777 (0.276–2.184) 0.632 1.639 (0.548–4.901) 0.377 1.912 (0.843–4..338) 0.121 1.000 (0.357–2.798) 0.999 3.576 (1.010–12.658) 0.048
Preoperative EBV DNA 1.546 (0.758–3.151) 0.231 5.535 (1.677–18.268) 0.005 1.898 (0.655–5.499) 0.238 1.571 (0.733–3.365) 0.245 2.622 (0.944–7.286) 0.064 2.804 (1.018–7.727) 0.046
Postoperative pathological result 5.209 (1.185–22.900) 0.029 9.265 (1.035–82.935) 0.047 10.175 (1.273–81.320) 0.029 4.158 (0.457–37.820) 0.206
Treatment for NPC 1.282 (0.780–2.108) 0.327 1.702 (0.711–4.070) 0.232 2.619 (0.929–7.383) 0.069 1.141 (0.672–1.938) 0.626 0.865 (0.476–1.573) 0.635 2.398 (0.971–5.922) 0.058
  1. NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, HR hazard ratio, CI confidence interval
  2. All variables were transformed into categorical variables. HRs were calculated for age (≥ 45 vs. < 45 years), sex (male vs. female), T stage (3–4 vs. 1–2), N stage (3 vs. 1–2), clinical stage (IV vs. III vs. II), EBV DNA before first treatment (> 4000 vs. ≤ 4000 copies/mL), preoperative EBV DNA (> 0 vs. 0 copy/mL), postoperative pathology (positive vs. negative), and treatment for NPC (RT vs. CCRT vs. NAC + CCRT vs. CCRT + AC)